with rosiglitazone have created huge uncertainty in patients, physicians and other healthcare providers. A meta-analysis by Nissen et al. included 42 controlled studies with rosiglitazone over a minimum duration of 24 weeks in which data on MI and CV death were available. 1 The analysis suggests a 1.43fold increased relative risk for MI and a 1.64-fold increase in CV death risk in patients treated with rosiglitazone compared to those not receiving this agent. In this issue of Diabetes and Vascular Disease Research, Dr McGuire nicely puts into perspective this study by discussing the statistical and analytical problems of this meta-analysis, some of which are also addressed by the authors themselves in their manuscript (see pages 77-9, doi:10.3132/dvdr.2007.022). In a subsequent issue of the New England Journal of Medicine Home et al. published an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD) trial, investigating the effect of rosiglitazone on CV outcome in a total of 4,447 patients with diabetes. 2 Looking at adjudicated events, this analysis, performed after 3.75 years, did not find a significant increase in the incidence of MI or CV death or in the combined primary end point of hospitalisation or death from cardiovascular causes. Overall, there was an 8% non-significant increase in the primary end point in patients receiving rosiglitazone (in combination with metformin or sulfonylurea), compared to those receiving combination therapy of metformin and sulfonylurea, but the total number of events was low. The authors concluded that their interim findings were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalisation or death from cardiovascular causes, with no evidence of any increase in death from either cardiovascular causes or all causes. Interestingly, the study's data and safety monitoring board has recommended continuation of the trial and final results can be expected in 2009.
What is a cardiologist's view on these data? First of all, it has to be mentioned that cardiologists are spoiled with respect to large outcome trials on CV events. For many therapeutic interventions in cardiology we have the benefit of a large database of randomised studies which helps to guide our therapy. This is somewhat different in the diabetes field. For years, the metformin subgroup results from the United Kingdom Prospective Diabetes Study (UKPDS) have been considered the landmark data on CV events in patients with diabetes 3 and only recently the results of the PROActive trial with pioglitazone have provided some additional data on CV outcome in patients treated with antidiabetic drugs. 4 Concerning the meta-analysis by Nissen et al., it is important to note that none of the studies included were designed and powered to address CV end points and that the absolute event rate was very low, with about 0.6% for MI in both groups, those treated with rosiglitazone as well as in otherwise-treated patients. In addition, patient populations in the different trials analysed were very heterogeneous with respect to their CV risk, ranging from impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) patients to those with longstanding diabetes. With respect to the interim analysis by Home and colleagues, the authors note that these "data do not allow a conclusion as to whether treatment with rosiglitazone results in a higher rate of myocardial infarction than does therapy with metformin or a sulphonylurea", which seems appropriate given the nature of this unplanned analysis. However, as previously seen in PROActive with pioglitazone, rosiglitazone significantly increased the risk of heart failure in this study, underscoring the problem of fluid retention and volume overload in certain patients undergoing thiazolidinedione (TZD) treatment.
Given recent publications on CV surrogate parameters and TZD therapy, the increase in MI and CV events suggested by Nissen's report is somewhat surprising. Various studies in patients with or without diabetes have demonstrated, for instance, a decrease in C-reactive protein, 5 an improvement in endothelial function, 6 a reduction in restenosis after coronary intervention 7 and plaque stabilisation by TZD treatment, 8, 9 suggesting vasoprotective and beneficial CV effects of these agents. Still, to date we lack evidence that an improvement of any of these surrogate parameters influences CV risk and this needs to be taken into account when interpreting the results.
Putting all this together, the recent publication by Nissen and colleague on rosiglitazone and CV risk raises the hypothesis that TZD treatment may increase the risk of MI and CV events. This hypothesis now needs further evaluation and the final results of the three large-scale prospective trials (RECORD, Bypass Angioplasty Revascularization Investigators 2 Diabetes [BARI-II] and Action to Control Cardiovascular Risk in Diabetes [ACCORD]) with rosiglitazone will certainly provide an answer here. In general, subgroup analyses and meta-analyses can help to generate new scientific questions and hypotheses, but the prospective, well designed and sufficiently powered study is still the gold standard. Recent results from the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) ramipril arm underscore this very impressively: a meta-analysis of retrospective data from Prevention of Events with Angiotensin-Converting Enzyme inhibition (PEACE), the European trial on Reduction of cardiac events with Perindopril in stable coronary artery disease (EUROPA) MEDICINE AND THE MEDIA Rosiglitazone and cardiovascular disease: a cardiologist's perspective and Heart Outcomes Prevention Evaluation (HOPE) suggested that angiotensin-converting enzyme (ACE) inhibitors could reduce the risk of diabetes development by 14% 10 but only the prospective DREAM trial, published last year, revealed little or no beneficial effect of ramipril on the incidence of diabetes. 11 Similarly, the meta-analysis on rosiglitazone and CV events raises the question of CV safety of this drug and this definitely needs to be answered in the upcoming studies, but we should not panic and frighten patients and healthcare providers. The cardiology community recently experienced a similar situation when retrospective analyses questioned the safety of drug-eluting stents but everyone involved, physicians, the Food and Drugs Administration (FDA) and industry, approached this issue in a very structured and collaborative way, as recently described in a special report by Krucoff et al. 12 The question of CV risk in rosiglitazone-treated patients should be addressed using a similar collaborative approach and, most importantly, further sensationalising reports in the media should be avoided.
